NAVCO Pharmaceuticals Inc. reported earnings results for the second quarter and six months ended March 31, 2024. For the second quarter, the company reported net loss was CAD 0.396489 million compared to CAD 0.043225 million a year ago. Basic loss per share from continuing operations was CAD 0.01. Diluted loss per share from continuing operations was CAD 0.01.
For the six months, net loss was CAD 0.668437 million compared to CAD 0.138494 million a year ago. Basic loss per share from continuing operations was CAD 0.01 compared to CAD 0.01 a year ago. Diluted loss per share from continuing operations was CAD 0.01 compared to CAD 0.01 a year ago.